Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) ...
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of ...
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and ...
Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation The granted patent covers claims ...
GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...
Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular ...
Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in immunotherapy. P-selectin glycoprotein ligand 1 (PSGL-1) is known to exert ...
The buzzy term gets blamed for many diseases. But it isn’t all bad. Credit...Pete Gamlen Supported by By Nina Agrawal Illustrations by Pete Gamlen Inflammation has become a bit of a dirty word. We ...
Inflammation is an immune response from the body’s immune system when there is a perceived injury or infection. When injured, inflammation causes the area to become red and swell due to a large number ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results